A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. - Wikidata - awgldk - TriplyDB

A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration.

A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration.

http://www.wikidata.org/entity/Q38119707

about

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept Defining response to anti-VEGF therapies in neovascular AMD The design and implementation of a study to investigate the effectiveness of community vs hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease.Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials The concordance of care for age related macular degeneration with the chronic care model: a multi-centered cross-sectional study.Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure.Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy.Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcome The Chronic Care for Wet Age Related Macular Degeneration (CHARMED) Study: A Randomized Controlled Trial.Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes Six-year outcomes in neovascular age-related macular degeneration with ranibizumab.Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration.Ocular Infection: Endophthalmitis Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.Stenotrophomonas maltophilia: An emerging entity for cluster endophthalmitis.Induced pluripotent stem cell-based therapy for age-related macular degeneration.The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age-related macular degeneration.Long-Term Outcomes in Patients with Neovascular Age-Related Macular Degeneration Who Maintain Dry Macula after Three Monthly Ranibizumab Injections.[Atrophy of the macula in the context of its wet, age-related degeneration : An inescapable consequence of anti-VEGF therapy?]

P2860

Q26786766-979A9688-54E5-4608-AF99-7C90F97A6C15 Q26996510-3A18CAFC-B887-47A6-947D-CD3314C098E3 Q27324293-B244D59A-FE75-4BCC-B2B6-9FA1567BAF57 Q28049700-3B77C455-FA55-488A-8572-DE549C3D828D Q34301308-72C62956-0542-4671-BB24-FFF4E021E406 Q34610139-3ED7E48C-1879-4566-8552-3C5A45C9B9C3 Q34953629-60609A0C-AEB2-42C5-9D52-C9505800A71F Q35368673-DAE2B071-5E39-4502-9BF0-EA66CE424BA8 Q35503206-35F16E81-6BA6-4D3B-98A7-9BEDBE3B57AA Q35841740-4005F0C6-E1D4-4582-BE8D-4535F0A4968D Q35902212-9EB51347-3EC6-4648-8164-D391227687DB Q36763595-71C6AF88-8BA7-4ECE-9338-4937ADB9C2F5 Q37578627-48622285-E954-49C4-9764-817AFAD5053D Q37702363-446B9BD4-19CB-4A05-A4AC-51CDBACF26D7 Q38616486-05888EC9-D8E9-4868-84EF-2066D97548C4 Q41973171-744DB54F-CE56-44F4-8E00-6BD63C4C1B8E Q43364243-BCCCC73A-B171-41EA-AC89-F7F1CB2A45F8 Q47406772-DE1ACC2A-8160-44DE-8CA9-CC6B1FE9A5A6 Q48218214-14336522-5678-403B-A26F-7837FAD57A41 Q50903375-294E49F6-742E-4BFC-8C00-A248AC03CBD9 Q52677250-FB3E35E6-8BC9-47B8-BC28-2154B2F4C66B Q53018746-FF1F06A7-32A2-40BB-9D49-E5C5B7608DEB

P2860

A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration.

http://www.wikidata.org/entity/Q38119707

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

A 4-year longitudinal study of ...... -related macular degeneration.

@en

type

label

A 4-year longitudinal study of ...... -related macular degeneration.

@en

prefLabel

A 4-year longitudinal study of ...... -related macular degeneration.

@en

P1433

Q38119707-EF46EDA9-5215-4A20-A374-870223CDA9C4

P1476

Q38119707-5F8AA46B-CACE-45A5-A4A9-96B830D75B2A

P2093

Q38119707-1B2CAFAD-0990-45B6-B942-429C976DC343

Q38119707-2DF82D6D-C0A5-4FB2-B70C-FBBF02B2952B

Q38119707-523442F1-EF8B-4E28-8262-133CDEC1408C

Q38119707-7AF4A70D-A06F-4125-909B-D2CFC3F38AEC

Q38119707-B955B6A3-F418-4ADF-B1E0-721485298812

Q38119707-BC21F156-4FED-4468-AC53-2C4B407601AA

Q38119707-F5E8DAAA-7308-4ECF-8359-49EA76F75B8B

Q38119707-FB68D537-DB33-4C3D-A6C8-8D660366611B

P304

Q38119707-2274E83B-931B-4C62-9BCB-D18CAE87D665

P31

Q38119707-CDB45729-6BC8-4857-BDBA-B0F4A99F6803

P356

Q38119707-989D4145-71FB-4ECF-BD26-E7F40D72AC39

P433

Q38119707-394AFC09-9FCD-45BA-A0BE-94793714E13C

P478

Q38119707-56E71163-601A-40C8-BA7C-58A1DAB28F53

P577

Q38119707-AD83F9B1-7CD5-4116-B9DE-CDB542686028

P698

Q38119707-ECE492F8-9511-4C4A-919D-F79B31B0F8F2

P356

J.OPHTHA.2013.05.018

P1433

P1476

A 4-year longitudinal study of ...... -related macular degeneration.

@en

P2093

Annette Rasmussen

http://www.w3.org/2001/XMLSchema#string

Birgit Sander

http://www.w3.org/2001/XMLSchema#string

Henrik Lund-Andersen

http://www.w3.org/2001/XMLSchema#string

Josefine Fuchs

http://www.w3.org/2001/XMLSchema#string

Louise H Hansen

http://www.w3.org/2001/XMLSchema#string

Michael Larsen

http://www.w3.org/2001/XMLSchema#string

Morten Lacour

http://www.w3.org/2001/XMLSchema#string

Sara B Bloch

http://www.w3.org/2001/XMLSchema#string

P304

2630-2636

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2013.05.018

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23830760

http://www.w3.org/2001/XMLSchema#string